JAHA:卡维地洛与美托洛尔对伴有和不伴有2型糖尿病的心衰患者长期死亡率影响的比较

2021-09-17 MedSci原创 MedSci原创

在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。

与美托洛尔相比,卡维地洛可能具有良好的降血糖特性,但在2型糖尿病(T2D)和射血分数降低的心力衰竭(HFrEF)患者中,卡维地洛与美托洛尔相比是否具有更好的死亡率益处尚未明确。

近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员使用了2010年至2018年期间丹麦的全国数据库,对接受卡维地洛或美托洛尔治疗的新发HFrEF患者的全因死亡率进行了随访,直至2018年底。在HFrEF诊断后120天开始随访,以启动指南定向的药物治疗。

基线时有39260名患者使用卡维地洛或美托洛尔(平均年龄为70.8岁,35%为女性),其中9355名(24%)患者伴有T2D。2989名(32%)T2D患者和10411(35%)名非T2D患者服用了卡维地洛。卡维地洛使用者的房颤患病率较低(20% vs. 35%),但其他特征在各组之间似乎很平衡。到随访结束时,共有11306名(29%)患者死亡。

研究人员观察到卡维地洛和美托洛尔组间的死亡率没有差异,T2D患者的多变量调整风险比(HR)为0.97(0.90-1.05),而没有T2D的患者则为1.00(0.95–1.05),差异P=0.99。与美托洛尔相比,卡维地洛使用者的新发T2D发生率较低;年龄、性别和年份调整后的HR为0.83(0.75-0.91),P<0.0001。
 
在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。

原始出处:

Brian Schwartz.et al.Long‐Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study.JAHA.2021.https://www.ahajournals.org/doi/10.1161/JAHA.121.021310

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-10-04 1def6e10m76(暂无匿称)

    #糖尿病#在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-09-19 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-09-18 ms1000002136354097

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-09-18 谭桂峰

    与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-09-17 ms2000000997930621

    真的是学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-09-17 misszhang

    谢谢MedSci提供最新的资讯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2071043, encodeId=2b5e20e104366, content=<a href='/topic/show?id=77f4365313f' target=_blank style='color:#2F92EE;'>#卡维地洛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36531, encryptionId=77f4365313f, topicName=卡维地洛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Feb 14 03:21:22 CST 2022, time=2022-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057393, encodeId=02e2105e393f5, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>在伴有和不伴有T2D的HFrEF患者当代临床队列中,与美托洛尔相比,卡维地洛与降低长期死亡率无关。然而,卡维地洛与新发T2D风险降低相关,支持卡维地洛比美托洛尔具有更好的代谢特性这一论断。, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 08:53:53 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268631, encodeId=ec36126863113, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337151, encodeId=e1b5133e15183, content=<a href='/topic/show?id=428fe9954c0' target=_blank style='color:#2F92EE;'>#美托洛尔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79954, encryptionId=428fe9954c0, topicName=美托洛尔)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373541, encodeId=3db813e3541b8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Sun Sep 19 10:21:22 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052482, encodeId=f6e21052482e5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1e05489924, createdName=ms1000002136354097, createdTime=Sat Sep 18 06:36:05 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052480, encodeId=c1921052480ef, content=与美托洛尔相比,卡维地洛可能具有良好的降血糖特性。, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=谭桂峰, createdTime=Sat Sep 18 06:11:14 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052437, encodeId=87e5105243e2c, content=真的是学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f72a5537728, createdName=ms2000000997930621, createdTime=Fri Sep 17 22:27:20 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052701, encodeId=359f1052e01af, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Sep 17 22:21:22 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052392, encodeId=b4b81052392de, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e8212476654, createdName=1244c0ebm28暂无昵称, createdTime=Fri Sep 17 20:49:08 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-09-17 1244c0ebm28暂无昵称

    学习学习

    0

相关资讯

Circ-Heart Fail:中国城市心衰患病率和发病率分析

HF给我国卫生系统带来了相当大的负担,急需开发针对HF防治的策略。

J Clin Oncol:依鲁替尼治疗可明显增加CLL患者的房颤、出血和心衰风险

依鲁替尼治疗可明显增加CLL患者的房颤、出血和心衰风险

Heart:Graves'病患者心衰发生率、危险因素、病程和结局

5.4%的GD患者发生新发HF,并且与心血管住院和死亡风险增加相关,其危险因素包括房颤、较高的TRAb、较高的BMI和明显的甲状腺功能亢进。

张健教授点评:GUIDE-HF研究——早期心衰患者或将从血流动力学检测中得到更多获益

2021年8月27日,GUIDE-HF研究随机组主要终点数据在ESC 2021会议上正式公布。继CHAMPION研究证实基于CardioMEMS植入式传感器进行肺动脉压力引导的心衰管理能有效降低NYH

Circ Heart Fail:杨杰孚/詹思延团队揭示中国城市人口的心衰患病率、发病率及医疗费用状况

早在2000年,国内一项心衰研究调查了十个省份内的15518名参与者,年龄35-74岁,结果得出心衰患病率为0.9%。在2012-2015年间的中国高血压调查中,分析了22158名参与者,其中35岁以

Lancet:血流动力学指导下的心力衰竭管理,或许并不能降低死亡率

血流动力学指导下的心力衰竭管理并没有导致死亡率和总心力衰竭事件的综合终点率降低,但降低了COVID-19期间心衰住院率。